10-K: Hestia Insight Pivots to AI Amidst Steep Revenue Decline

Sentiment:

Annual Report


Hestia Insight Inc. announced a strategic pivot to AI-powered advisory services, alongside a significant drop in annual revenue and a substantial net loss, raising going concern doubts.

Capital raiseThe Board of Directors approved a capital raise of up to $5 million.This will be executed through a combination of equity offerings and/or convertible debt instruments.Proceeds will be allocated toward expansion of the AI development team, acceleration of research and development initiatives, marketing and deployment of AI-powered consulting tools, and general corporate purposes.
Worse than expectedRevenue decreased by $1,241,884, from $1,249,884 in 2024 to $8,000 in 2025.The company reported a net loss of $(943,444) in 2025, a significant decline from a net income of $642,205 in 2024.Accumulated deficit increased substantially from $(114,322) in 2024 to $(1,057,766) in 2025.Cash balances are insufficient to cover operating expenses for the next twelve months, leading to a going concern warning from the independent auditor.

Summary

  • Hestia Insight Inc. is transforming into an AI-powered capital markets advisory and business consulting firm, specializing in fundraising solutions for emerging growth companies.
  • The company will discontinue its legacy operations in Healthy Vending Services and Portable Charging Network Business to streamline resources.
  • Revenue for the fiscal year ended November 30, 2025, was $8,000, a drastic decrease from $1,249,884 in 2024.
  • The company reported a net loss of $(943,444) for 2025, compared to a net income of $642,205 in 2024.
  • Accumulated deficit grew from $(114,322) in 2024 to $(1,057,766) in 2025.
  • Cash balances decreased from $41,163 in 2024 to $28,871 in 2025.
  • The Board of Directors approved a capital raise of up to $5 million through equity offerings and/or convertible debt to fund AI development, R&D, marketing, and general corporate purposes.
  • The company's independent auditor raised substantial doubt about its ability to continue as a going concern due to insufficient cash and operating losses.
  • Management identified material weaknesses in internal control over financial reporting due to limited resources and lack of segregation of duties.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative filing due to the drastic revenue decline, substantial net loss, significant accumulated deficit, and the explicit going concern warning from the auditor, despite the strategic pivot to AI.

Positives

  • Strategic pivot to AI-powered capital markets advisory and business consulting, focusing on high-growth potential in healthcare and biotech sectors.
  • Board approval for a capital raise of up to $5 million to fund AI development and growth initiatives.
  • Discontinuation of unprofitable legacy operations (Healthy Vending Services and Portable Charging Network Business) to streamline resources and focus.
  • Eugene Cha was appointed as an independent director on January 4, 2024, improving board independence.

Negatives

  • Revenue plummeted from $1,249,884 in 2024 to $8,000 in 2025, a decrease of $1,241,884.
  • Net income swung from a profit of $642,205 in 2024 to a net loss of $(943,444) in 2025.
  • Accumulated deficit significantly increased from $(114,322) in 2024 to $(1,057,766) in 2025.
  • Cash balance decreased to $28,871 as of November 30, 2025, with insufficient cash to cover operating expenses for the next twelve months.
  • The independent auditor expressed substantial doubt about the company's ability to continue as a going concern.
  • Material weaknesses identified in internal control over financial reporting due to limited staff and lack of segregation of duties.
  • Significant related party loans totaling $173,931 as of November 30, 2025, primarily from Edward Lee and ECL Capital Partners Corp.
  • Market value of common stock held by non-affiliates was $1,369,024 as of November 30, 2025, indicating a small market capitalization.
  • Stock price volatility and thin trading on OTC Markets, with the closing price at $0.049 per share on November 30, 2025.
  • The company has never paid dividends and does not intend to in the foreseeable future.

Risks

  • Limited operating history and limited revenue make future performance difficult to forecast.
  • Inability to effectively manage growth of operations.
  • Business requires substantial capital, and inability to maintain adequate financing sources will jeopardize operations.
  • Revenue and results of operations may suffer if unable to attract new clients, engage existing clients, or sell additional products and services.
  • Inability to maintain reputation and expand name recognition.
  • Failure to offer new and valuable products and services.
  • Significant delays in generating revenue if potential clients take a long time to evaluate products and services.
  • Potential liability claims from consulting services.
  • Investments in companies for strategic reasons may not realize a return.
  • Intense competition in healthcare markets.
  • Status as an Emerging Growth Company may result in reduced disclosure obligations, making investing less attractive.
  • Contingent or unknown liabilities could materially and adversely affect the business.
  • Expenses required to operate as a public company will reduce funds available for business development.
  • Growth depends on external sources of capital, which may not be available on favorable terms or at all.
  • Future indebtedness reduces cash available for distribution and may expose to default risk.
  • Risk of being deemed an investment company under the Investment Company Act of 1940 if business practices are not carefully managed.
  • Dependence on key personnel for success; departure could have material adverse effect.
  • Board of directors may change investment or operation objectives and strategies without shareholders' consent.
  • Past operating losses raise doubt about ability to continue as a going concern.
  • Inability to attract and retain qualified, experienced, highly skilled personnel.
  • Strategic consulting and capital market advisory services affected by COVID-19 pandemic.
  • Current political tension between the United States and China can adversely affect the Company due to limited operations in China.
  • Dilution of ownership if new common stock or other securities are issued.
  • Lack of voluntarily implemented corporate governance measures (e.g., independent audit committee, Code of Ethics not yet adopted).
  • Exposure to potential risks relating to internal control over financial reporting, including identified material weaknesses.
  • Large number of authorized but unissued shares of common stock could cause dilution.
  • Shares may continue to be subject to illiquidity due to thin trading and potential ineligibility for national securities exchange listing.
  • Market valuation may fluctuate due to factors beyond control.
  • No dividends paid or expected.
  • Difficulty attracting brokerage firm attention due to reverse acquisition.
  • Difficulty retaining or attracting qualified officers and directors due to regulatory requirements.
  • Failure to maintain effective internal controls could lead to inaccurate financial reports or fraud.
  • Voting power highly concentrated by insiders (68.48%).
  • Board can create new series of preferred stock without shareholder approval, potentially adversely affecting common stockholders.
  • Trading limited under SEC's penny stock regulations.

Future Outlook

Hestia Insight is strategically transforming into an AI-powered technology company, focusing on developing and commercializing AI-powered solutions for business consulting and capital market advisory services, particularly for fundraising. This includes AI-enhanced pre-raise strategy, market research, investor materials, and investor outreach. The company plans to aggressively seek licensing or representation for other exceptional products in its focus areas, aiming to assist startups, small businesses, and growth-stage companies in accelerating their go-to-market strategies and preparing for investment readiness.

Management Comments

  • "Hestia Insight Inc. has made the strategic decision to evolve into a full-fledged Artificial Intelligence (AI) technology company."
  • "This transformation will position Hestia Insight to develop and commercialize AI-powered solutions for business consulting and capital market advisory services."
  • "Hestia Insight is committed to helping clients navigate the complexities of capital raising in today's competitive marketplace."
  • "Management of the Company believes that these material weaknesses are due to the small size of the Company's accounting staff and reliance on outside consultants for external reporting."
  • "To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of legal and outside accounting consultants."
  • "As we grow, we expect to increase our number of employees, which will enable us to implement adequate segregation of duties within the internal control framework."

Industry Context

StockSavvy.ai notes that Hestia Insight's pivot to AI-powered capital markets advisory aligns with a broader industry trend of leveraging artificial intelligence to enhance efficiency and insights in financial services and consulting. Many traditional advisory firms are integrating AI for data analysis, predictive modeling, and automated client engagement. However, Hestia Insight's focus on "emerging growth companies" in healthcare and biotech, combined with its "proprietary artificial intelligence platform," positions it in a niche that could offer significant value if successfully executed, differentiating it from larger, more generalized AI consulting providers. The discontinuation of legacy vending and charging businesses reflects a necessary streamlining to focus on this high-potential, yet competitive, technology-driven sector.

Comparison to Industry Standards

  • StockSavvy.ai observes that Hestia Insight's current financial performance, with a significant revenue decline to $8,000 and a net loss of $(943,444) in FY2025, falls substantially below the typical revenue and profitability benchmarks for established capital markets advisory firms or AI-driven consulting companies.
  • Compared to well-known financial advisory firms like Goldman Sachs or Morgan Stanley, or even specialized boutique investment banks, Hestia Insight's revenue is negligible, reflecting its early stage and "smaller reporting company" status.
  • In the AI consulting space, companies like Accenture or Deloitte, which have robust AI divisions, report billions in revenue, making direct comparison impractical. Even smaller, specialized AI startups typically demonstrate higher revenue growth or clearer paths to profitability than Hestia Insight's current figures.
  • The accumulated deficit of $(1,057,766) and the going concern warning are critical indicators that Hestia Insight is far from industry standards for financial stability and operational maturity.
  • The reliance on related party loans and the identified material weaknesses in internal controls also suggest a governance and operational structure that is not yet aligned with best practices seen in more mature or well-capitalized industry players.

Management Changes

RolePrevious PersonNew PersonEffective DateReason
Chief Executive Officer, President, Chief Financial Officer, Treasurer, Secretary, and Chairman of the BoardN/AEdward C. LeeMarch 6, 2019Appointed as sole officer and director.
Independent DirectorN/AEugene ChaJanuary 4, 2024Appointment to the Board.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Audit CommitteeThe Board of Directors acts as the Audit Committee; no separate committee exists. No qualified financial expert is on the board due to inadequate financial resources.N/AIncreases risk of financial reporting errors and lack of independent oversight.
Code of EthicsBoard plans to adopt a written code of business conduct and ethics at a future meeting.FutureCurrent absence may lead to less defined standards for responsible conduct.
Director IndependenceThe company currently has only one independent director (Eugene Cha) and intends to expand board membership in future periods to include more independent directors.N/ALimited independent oversight on key corporate decisions, including executive compensation and director nominees.
Nominating CommitteeNo procedures adopted for security holders to recommend nominees to the Board of Directors.N/ALimits shareholder influence on board composition.
Internal ControlsManagement concluded disclosure controls and procedures were ineffective as of November 30, 2025, due to limited resources and lack of segregation of duties. Material weaknesses identified in internal control over financial reporting.N/AIncreases risk of misstatement of financial data and potential fraud.

Legal Proceedings

  • The company is not currently a party to any material legal proceedings.
  • No pending legal proceedings or claims.

Related Party Transactions

  • On January 15, 2024, a $50,000 note payable to ECL Capital Partners Corp. (related party) at 6.00% interest, extended to January 15, 2026.
  • In August 2024, a $3,931 short-term, interest-free loan from Mr. Edward C. Lee (related party).
  • On August 25, 2024, a $25,000 note payable to ECL Capital Partners Corp. at 6.00% interest, due August 24, 2025.
  • On February 17, 2025, a $25,000 note payable to Mr. Edward Lee at 6.00% interest, due February 17, 2026.
  • On March 17, 2025, a $25,000 note payable to Mr. Edward Lee at 6.00% interest, due March 17, 2026.
  • On June 30, 2025, a $10,000 note payable to Mr. Edward Lee at 6.00% interest, due June 30, 2026.
  • On July 31, 2025, a $12,500 note payable to Mr. Edward Lee at 6.00% interest, due July 31, 2026.
  • On October 17, 2025, a $12,500 note payable to Mr. Edward Lee at 6.00% interest, due October 17, 2026.
  • On November 24, 2025, a $10,000 note payable to Mr. Edward Lee at 6.00% interest, due November 24, 2026.
  • Total outstanding balance due to related parties as of November 30, 2025, was $173,931.

Stakeholder Impact

  • Shareholders: Significant dilution risk from future equity raises, potential loss of investment due to going concern doubts, limited influence due to concentrated voting power, no dividends expected, and illiquidity of common stock.
  • Employees: Small number of employees (3), reliance on independent contractors, potential for increased hiring as the company grows, but also risk if the company fails to secure funding.
  • Customers (Clients): Potential for enhanced AI-powered advisory services, but also risk if the company's financial instability impacts service delivery or long-term viability.
  • Creditors: Exposure to risk due to the company's going concern issues and reliance on related party loans.

Next Steps

  • Expand the AI development team.
  • Accelerate research and development initiatives for AI-powered solutions.
  • Market and deploy AI-powered consulting tools.
  • Seek licensing or representation for other exceptional products in focus areas.
  • Raise up to $5 million in capital through equity offerings and/or convertible debt.
  • Increase the number of employees to implement adequate segregation of duties within the internal control framework.
  • Adopt a written code of business conduct and ethics.
  • Expand board membership in future periods to include independent directors.

Key Dates

DateDescription
November 19, 2003Incorporated in Nevada as Luxshmi Investments, Inc.
March 6, 2019Edward C. Lee appointed as the company's sole officer and director.
March 12, 2019Filed Certificate of Amendment to Articles of Incorporation, authorizing 300,000,000 shares of capital stock.
March 27, 2019Name changed to Hestia Insight Inc. and effected a 50-to-1 reverse stock split.
May 16, 2019Entered Share Exchange Agreement with Hestia Investments Inc., making Hestia Investments a wholly owned subsidiary.
December 1, 2019Independent Consulting Agreement with BHPA Inc.
June 21, 2020Sales Agency Agreement with Immudyne Nutritional.
May 24, 2021Board and stockholders approved the 2021 Stock Incentive Plan.
January 4, 2022Eugene Cha appointed as an independent director.
December 15, 2022Issued stock option to Dr. T.Z. (Ted) Chaung, Advisory Board member.
January 15, 2024Entered into a $50,000 note payable to ECL Capital Partners Corp., extended until January 15, 2026.
July 24, 2024BF Borgers CPA PC resigned as independent auditor; Victor Mokuolu, CPA PLLC engaged as new auditor.
August 2024Received an additional loan of $3,931 from Mr. Edward C. Lee.
August 25, 2024Entered into a $25,000 note payable to ECL Capital Partners Corp., due August 24, 2025.
November 30, 2024Fiscal year ended.
December 1, 2024Adopted ASU 2024-07, Segment Reporting.
December 2024FASB issued ASU 2024-09, Income Taxes (effective for fiscal years beginning after December 15, 2025).
February 17, 2025Entered into a $25,000 note payable to Mr. Edward Lee, due February 17, 2026.
March 17, 2025Entered into a $25,000 note payable to Mr. Edward Lee, due March 17, 2026.
June 10, 2025Board of Directors approved a compensation package for CEO Edward C. Lee.
June 25, 2025Issued stock options to Edward Lee (1,000,000 shares) and Eugene Cha (500,000 shares).
June 30, 2025Entered into a $10,000 note payable to Mr. Edward Lee, due June 30, 2026.
July 31, 2025Entered into a $12,500 note payable to Mr. Edward Lee, due July 31, 2026.
October 17, 2025Entered into a $12,500 note payable to Mr. Edward Lee, due October 17, 2026.
November 24, 2025Entered into a $10,000 note payable to Mr. Edward Lee, due November 24, 2026.
November 30, 2025Fiscal year ended. Market value of common stock held by non-affiliates was $1,369,024. Closing stock price was $0.049 per share.
December 31, 2025Determined to discontinue operations of HSTA Health Inc. (subsequent event).
March 2, 2026Date of filing. 27,939,260 shares of common stock outstanding.

Recommendation

strong sell

The company faces severe financial distress, evidenced by a near-total collapse in revenue (from $1.25 million to $8,000), a substantial net loss of nearly $1 million, and an accumulated deficit exceeding $1 million. The explicit "going concern" warning from the independent auditor, coupled with insufficient cash to cover operations for the next year, indicates a high probability of business failure or significant further dilution. While the strategic pivot to AI and a planned capital raise offer a glimmer of hope, the current financial state and operational weaknesses (e.g., ineffective internal controls, heavy reliance on related party financing) present an extremely high-risk profile. A seasoned investor would view this as a company struggling for survival, making it a strong sell to avoid further capital erosion.

Keywords

AI, Artificial Intelligence, Capital Markets Advisory, Fundraising, Emerging Growth Companies, Healthcare, Biotech, Consulting, SEC Filing, 10-K, Hestia Insight, HSTA, Financial Reporting, Corporate Governance, Risk Management, Going Concern, Stock Options, Related Party Transactions

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.